Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Ireland
  4. Irish Stock Exchange
  5. Uniphar plc
  6. Summary
    UPR   IE00BJ5FQX74

UNIPHAR PLC

(UPR)
  Report
Real-time Irish Stock Exchange  -  03:00 2022-08-17 am EDT
3.450 EUR   -1.43%
08/15Uniphar Reportedly in Talks to Buy Sam McCauley
CI
07/26Uniphar's H1 Organic Gross Profit Growth Reaches 5%
MT
07/26UNIPHAR : H1 2022 Trading Update & Notice of results
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Irish Stock Exchange
08/11/2022 08/12/2022 08/15/2022 08/16/2022 08/17/2022 Date
3.465(c) 3.495(c) 3.505(c) 3.5(c) 3.45 Last
59 400 88 444 37 711 490 003 1 500 Volume
+0.14% +0.87% +0.29% -0.14% -1.43% Change
More quotes
Estimated financial data (e)
Sales 2022 2 035 M 2 071 M 2 071 M
Net income 2022 50,2 M 51,1 M 51,1 M
Net Debt 2022 97,5 M 99,2 M 99,2 M
P/E ratio 2022 18,9x
Yield 2022 0,50%
Sales 2023 2 139 M 2 177 M 2 177 M
Net income 2023 56,1 M 57,1 M 57,1 M
Net Debt 2023 77,4 M 78,7 M 78,7 M
P/E ratio 2023 17,0x
Yield 2023 0,53%
Capitalization 956 M 972 M 972 M
EV / Sales 2022 0,52x
EV / Sales 2023 0,48x
Nbr of Employees 2 850
Free-Float 87,9%
More Financials
Company
Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the United Kingdom, the Benelux, the Nordics and the United States. The Company's vision... 
Read more
Sector
Drug Retailers
Calendar
08/30 | 02:00amEarnings Release
More about the company
Ratings of Uniphar plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about UNIPHAR PLC
08/15Uniphar Reportedly in Talks to Buy Sam McCauley
CI
07/26Uniphar's H1 Organic Gross Profit Growth Reaches 5%
MT
07/26UNIPHAR : H1 2022 Trading Update & Notice of results
PU
05/11Uniphar's Organic Gross Profit Climbs 9% In 2021
MT
05/11UNIPHAR PLC : Proxy Statments
CO
04/07UNIPHAR PLC : Mixed general shareholder meeting
CO
03/01TRANSCRIPT : Uniphar plc, 2021 Earnings Call, Mar 01, 2022
CI
03/01Uniphar's FY21 Profit Jumps on Higher Revenue
MT
03/01Earnings Flash (UPR.L) UNIPHAR Reports FY21 EPS EUR0.18
MT
03/01Uniphar plc Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/01Uniphar plc Proposes Final Dividend, to Be Paid on 13 May 2022
CI
02/21UNIPHAR PLC : Crossing thresholds
CO
01/26Uniphar Confirms FY21 Outlook as Organic Gross Profit Rises Over 8%
MT
2021FTSE 100 Ends Thursday in Festive Mood as Omicron Fears Fade
DJ
2021Sterling Rises, But Selling Could Resume in 2022
DJ
More news
News in other languages on UNIPHAR PLC
08/15Uniphar serait en pourparlers pour racheter Sam McCauley
07/26La croissance organique de la marge brute d'Uniphar au premier semestre atteint 5 %.
05/11AVIS D'ANALYSTES DU JOUR : Gecina, Bayer, Crédit Suisse, Telia, NRJ Group, EMS-Chemie, Cla..
05/11La marge brute organique d'Uniphar grimpe de 9% en 2021
03/01Le bénéfice d'Uniphar pour l'exercice 21 bondit en raison de l'augmentation des recette..
More news
Analyst Recommendations on UNIPHAR PLC
More recommendations
Chart UNIPHAR PLC
Duration : Period :
Uniphar plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNIPHAR PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 3,50 €
Average target price 4,63 €
Spread / Average Target 32,1%
EPS Revisions
Managers and Directors
Ger Rabbette Chief Executive Officer & Director
Tim Dolphin Chief Financial Officer & Director
Maurice Pratt Non-Executive Chairman
Paul Hogan Independent Non-Executive Director
Jeffrey Berkowitz Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
UNIPHAR PLC-30.00%972
MCKESSON CORPORATION50.40%53 732
WALGREENS BOOTS ALLIANCE, INC.-19.40%36 333
CARDINAL HEALTH, INC.36.22%19 114
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD-14.49%8 250
SINOPHARM GROUP CO. LTD.2.59%6 925